ライフサイエンスコーパス: hypoglycemic

1 sulinemic (0.2 units kg(-1) min(-1)), severe hypoglycemic (10-15 mg/dL) clamps for 3 h with continuou

2 cemia can be fatal, hyperinsulinemic, severe hypoglycemic (10-15 mg/dL) clamps were performed in Spra

3 3-h hyperinsulinemic (0.2 units/kg/min) and hypoglycemic (10-15 mg/dL) clamps were performed.

4 littermate controls were subjected to graded hypoglycemic (100, 70, 50, and 30 mg/dl) hyperinsulinemi

5 = 10 per group) underwent a hyperinsulinemic-hypoglycemic (2.6 mmol/L) clamp, either after a HIIT ses

6 ing hyperinsulinemic-euglycemic (5.0 mmol/L)-hypoglycemic (2.6 mmol/L) clamps in 11 healthy participa

7 All participants underwent a hypoglycemic (2.8 mmol/L) clamp after performing a bout

8 tep hyperinsulinemic euglycemic (5.0 mmol/L)-hypoglycemic (2.8 mmol/L) glucose clamp.

9 e imaging during euglycemic (5.0 mmol/L) and hypoglycemic (2.8 mmol/L) hyperinsulinemic clamps, we co

10 A 2-h hyperinsulinemic [hypoglycemic (2.8 mmol/l) or euglycemic (5.0 mmol/l)] cl

11 l/L) or hyperinsulinemic (812 +/- 50 pmol/L)-hypoglycemic (2.9 +/- 0.1 mmol/L) clamps.

12 Hyperinsulinemic euglycemic (5 mmol/L) and hypoglycemic (3 mmol/L) [1-(13)C]glucose clamps were per

13 tted to hyperglycemic (40% glucose i.v.) and hypoglycemic (5 U/kg insulin i.v.) challenges.

14 that in the VA: 35.3% versus 12.7% for oral hypoglycemics, 50.7% versus 18.2% for statins, 42.5% ver

15 ion 92.4 +/- 2.3 mg/dl) and hyperinsulinemic-hypoglycemic (52.9 +/- 4.8 mg/dl) clamps separated by at

16 hyperinsulinemic euglycemic (92+/-3 mg/dL) - hypoglycemic (53+/-1 mg/dL) clamp.

17 nsulinemic euglycemic (90 mg/dL x 1 h), then hypoglycemic (54 mg/dL x 2 h) clamps, in the morning and

18 olyphenol-enriched DSF exhibited significant hypoglycemic activities in C57bl/6J mice, and cranberry

19 the blood glucose level in rats derived from hypoglycemic activity of NOB.

20 enefits" of Empagliflozin Independent of Its Hypoglycemic Activity?

21 At least 1 episode of hypoglycemic adverse events occurred in 320 (10.6%) part

22 ither taking no medication or taking an oral hypoglycemic agent (with or without insulin) were classi

23 >/= 7.0 mmol/L) >/= 30 days apart, (ii) oral hypoglycemic agent use for >/= 30 consecutive days, (iii

24 load glucose >/=200 mg/dL, HbA1c >/=6.5%, or hypoglycemic agent use.

25 onic obstructive pulmonary disease, use of a hypoglycemic agent, lower activity level, higher New Yor

26 tory of angina pectoris or asthma, no use of hypoglycemic agent, more activity level, and lower New Y

27 , oral antiplatelet agents (13.3%), and oral hypoglycemic agents (10.7%).

28 derate periodontitis and healthy group: oral hypoglycemic agents (17.4% versus 16.8% versus 8.0%), CC

29 Basal insulin can be added to oral hypoglycemic agents (generally stopping sulfonylureas) i

30 r, age 18 years or older, taking 0 to 3 oral hypoglycemic agents (metformin, thiazolidinedione, sulfo

31 sions or patients taking any insulin or oral hypoglycemic agents 1 month or later after kidney transp

32 etes was ascertained by using information on hypoglycemic agents and serum glucose.

33 insulin monotherapy, is the addition of oral hypoglycemic agents associated with benefits (measured b

34 t amelioration of hyperglycemia by different hypoglycemic agents forestalled PI-producing ATM accumul

35 alpha-amylase, a therapeutic target for oral hypoglycemic agents in type-2 diabetes.

36 Only the associations with systemic hypoglycemic agents were greater than 1 mm Hg, a thresho

37 o drug dosing (eg, many antibiotics and oral hypoglycemic agents).

38 n of rosiglitazone, compared with other oral hypoglycemic agents, among 2393 long-term hemodialysis p

39 ns: the first (control) while receiving oral hypoglycemic agents, and the second after the addition o

40 Additionally, intake of oral hypoglycemic agents, calcium channel blockers (CCB), ins

41 These cells were then treated with the hypoglycemic agents, metformin, and insulin to assess fo

42 ose not fasting), the use of insulin or oral hypoglycemic agents, or self-reported history.

43 Compared with patients prescribed other oral hypoglycemic agents, patients prescribed rosiglitazone h

44 vels, lived in Eastern Europe or were taking hypoglycemic agents, were more likely to have impaired Q

45 ogues, antihypertensive agents, statins, and hypoglycemic agents, whereas in spite of the prominent r

46 theobromine in DFCP were associated with the hypoglycemic and anti-inflammatory effects observed.

47 Hypoxic mice became hypoglycemic and displayed impaired hepatic glucose prod

48 First, we found that DeltaNesp55(m) mice are hypoglycemic and have reduced stomach-to-body weight rat

49 genus, it was widely popular because of its hypoglycemic and hypolipidemic properties but various ca

50 The hypoglycemic and insulin-like effects of CE and CDSF may

51 ansplantation using stepped hyperinsulinemic-hypoglycemic and paired hyperinsulinemic-euglycemic clam

52 e phenomenon was recapitulated in vivo under hypoglycemic and postprandial (fed) conditions.

53 of patient-days classified as hyperglycemic, hypoglycemic, and at-goal (all measurements >/=3.9 and <

54 of age and became malnourished, underweight, hypoglycemic, and hypothermic.

55 d can potentially minimize the occurrence of hypoglycemic anomalies.

56 will introduce measures of adherence to oral hypoglycemic, antihypertensive, and cholesterol-lowering

57 lic triterpene from Olea europaea L., exerts hypoglycemic, antioxidant, cardioprotective and antitumo

58 inemic (0.2 units x kg(-1) x min(-1)) severe hypoglycemic ( approximately 11 mg/dl) clamp for 60 or 9

59 c-euglycemic (approximately 8.5 mmol/l) and -hypoglycemic (approximately 3.0 mmol/l) clamps were done

60 on AMPK to suppress oxidative stress in the hypoglycemic bone marrow environment.

61 Mice rendered hypoglycemic by a null mutation in the glucagon receptor

62 Here we show that in the hypoglycemic chicken retina, spontaneous episodes of SD

63 Day 2 consisted of a single 2-h hypoglycemic clamp (2.9 mmol/L) following either DHEA (1

64 During the subsequent hypoglycemic clamp (all measurements from baseline to th

65 < 0.02, n = 5) during a 2-h hyperinsulinemic-hypoglycemic clamp (glucose concentration 57.2 +/- 9.7 m

66 C]acetate infusion during a hyperinsulinemic-hypoglycemic clamp (n = 8).

67 -25) after GBP surgery with hyperinsulinemic-hypoglycemic clamp (stepwise to plasma glucose 2.7 mmol/

68 d with a stepped hyperinsulinemic euglycemic-hypoglycemic clamp and behavioral measures of interest i

69 However, at the end of the hypoglycemic clamp concentrations all of the above menti

70 zes glucagon and corticosterone responses to hypoglycemic clamp in diabetic rats.

71 pinephrine secretion during hyperinsulinemic/hypoglycemic clamp in rats.

72 consisted of a single-step hyperinsulinemic-hypoglycemic clamp of 2.9 mmol/l.

73 BA(A)) receptor agonist muscimol, prior to a hypoglycemic clamp or under baseline conditions.

74 lycemia test and a low-dose hyperinsulinemic-hypoglycemic clamp procedure.

75 bose to lower A1C to 6.7% and 2-day repeated hypoglycemic clamp studies before and after intensive th

76 ion of ephrinA5-Fc before a hyperinsulinemic hypoglycemic clamp study caused a reduction in the gluco

77 Subsequently, a hyperinsulinemic-hypoglycemic clamp study was performed.

78 re measured during baseline and a subsequent hypoglycemic clamp taking place in the morning.

79 nses to hypoglycemia were assessed using the hypoglycemic clamp technique.

80 Subsequently, these rats underwent a hypoglycemic clamp to assess hormone responses.

81 ts and nondiabetic control subjects during a hypoglycemic clamp using (13)C magnetic resonance spectr

82 hormones measured at the end of the 240-min hypoglycemic clamp were not affected by TSD it can be sp

83 2 consisted of a single 2-h hyperinsulinemic-hypoglycemic clamp.

84 related hormones during a subsequent 240-min hypoglycemic clamp.

85 fusion followed by a 2-hour hyperinsulinemic/hypoglycemic clamp.

86 Day 1 consisted of morning and afternoon 2-h hypoglycemic clamps (2.9 mmol/L) with 800 mg of DHEA or

87 ) x min(-1)) euglycemic clamps (5.1 mmol/l), hypoglycemic clamps (2.9 mmol/l), or euglycemic clamps w

88 On day 2, subjects underwent stepped hypoglycemic clamps (nadir 60 mg/dL) with evaluation of

89 se to acute insulin-induced hypoglycemia and hypoglycemic clamps after modulation of brain NO signali

90 required lower glucose infusion rates during hypoglycemic clamps and displayed enhanced glucagon rele

91 Instead, lack of a glucagon response during hypoglycemic clamps identified impaired counterregulatio

92 ek later, animals underwent hyperinsulinemic-hypoglycemic clamps in which the hypoglycemic nadir, 2.4

93 otomy (TSV) were exposed to hyperinsulinemic-hypoglycemic clamps where glycemia was lowered slowly ov

94 afternoon 2-h hyperinsulinemic-euglycemic or hypoglycemic clamps with or without 1 mg alprazolam give

95 g and afternoon 2-h euglycemic or 2.9 mmol/L hypoglycemic clamps with or without 1 mg alprazolam give

96 Furthermore, during hyperinsulinemic-hypoglycemic clamps, ghrelin-KO mice required a 10-fold

97 l were studied with stepped hyperinsulinemic-hypoglycemic clamps, using hormone concentrations and gl

98 ine-specific neurotoxin and hyperinsulinemic-hypoglycemic clamps, we found that sympathoadrenal CRRs

99 ay 2 involved similar morning euglycemic and hypoglycemic clamps, with saline infusion, on all three

100 n metabolism during and after euglycemic and hypoglycemic clamps.

101 a (PIC): isoflurane (1.25%-1.5%) and induced hypoglycemic coma.

102 ent, 2-deoxyglucose (2-DG), under normal and hypoglycemic conditions and also after MAN lesioning wit

103 acellular Glu sustained cell viability under hypoglycemic conditions and increased GOT-mediated metab

104 ow that the degeneration of the macula under hypoglycemic conditions can be prevented by blocking ree

105 recurrent hypoglycemia under euglycemic and hypoglycemic conditions in a rat model and to test the h

106 ificantly different comparing euglycemic and hypoglycemic conditions in patients with T1DM.

107 ucose contribution to brain metabolism under hypoglycemic conditions that restored metabolic activity

108 advantage of preserving brain function under hypoglycemic conditions without causing deleterious hype

109 nversely related to the HbA1C and was, under hypoglycemic conditions, approximately 45% higher than t

110 that CD8(+) TILs reprogram under hypoxic and hypoglycemic conditions, regaining effector function by

111 cancer (PC-E1) were subjected to hypoxic and hypoglycemic conditions.

112 surement of low glucose concentrations under hypoglycemic conditions.

113 w the brain to function normally under acute hypoglycemic conditions.

114 evel of the VMH under both normoglycemic and hypoglycemic conditions.

115 h a truncated tricarboxylic acid cycle under hypoglycemic conditions.

116 5-h-fasted mice to assess insulin action and hypoglycemic counter-regulatory responsiveness.

117 Hypoglycemic detection at the portal-mesenteric vein (PM

118 The critical locus for hypoglycemic detection shifts away from the portal-mesen

119 iled to deploy electrocardiogram (ECG)-based hypoglycemic detection systems reliably.

120 been highlighted by the discovery of a novel hypoglycemic disorder in children, the hyperinsulinism-h

121 be corrected by treating cells with the oral hypoglycemic drugs sulfonylureas, which we have shown pr

122 mass index, glycated hemoglobin, use of oral hypoglycemic drugs, and smoking.

123 es glucose uptake in adipocytes and has oral hypoglycemic effect in wild-type C57BL/6J mice and db/db

124 n site (S436A) demonstrate resistance to the hypoglycemic effect of both insulin and metformin.

125 ex I abundance and sensitized animals to the hypoglycemic effect of metformin.

126 The hypoglycemic effect of Phellinus linteus polysaccharide

127 al IRs also resulted in a delay in the acute hypoglycemic effect of systemic insulin administration a

128 d for blueberry, demonstrating the potential hypoglycemic effect of the juices.

129 ractions among PLPE, gut microbiota, and the hypoglycemic effect remain unclear.

130 The samples showed a higher in vitro hypoglycemic effect than individual or mixed standards,

131 Pancreatic clamp studies revealed that this hypoglycemic effect was due to a decrease of hepatic glu

132 pe-II diabetes (T2D) treatment with superior hypoglycemic effect while also improving cardiovascular

133 er evaluated for its hypotriglyceridemic and hypoglycemic effects in high-fructose diet (HFD)-induced

134 -Tf exhibited a slow, but sustained, in vivo hypoglycemic efficacy and long plasma half-life.

135 in the insulin group, there was only 1 mild hypoglycemic episode (6%) in the metformin group, P < 0.

136 Neonatal hypoglycemic episode, defined as at least 1 consecutive

137 who were stratified according the number of hypoglycemic episodes (< 60 mg/dL glucose) they experien

138 ed dapagliflozin groups had a higher rate of hypoglycemic episodes (56.6% vs. 51.8%), events suggesti

139 3.77 to -2.64],P < .001) and fewer confirmed hypoglycemic episodes (episodes/patient-year exposure, 2

140 oints were the rate of nocturnal symptomatic hypoglycemic episodes (severe or blood glucose confirmed

141 nd point was the rate of overall symptomatic hypoglycemic episodes (severe or blood glucose confirmed

142 owest blood glucose concentration, number of hypoglycemic episodes and events, and negative interstit

143 Fewer hypoglycemic episodes and less weight gain occurred in p

144 s included the rate of nocturnal symptomatic hypoglycemic episodes and proportion of patients with se

145 ercent of all recipients were free of severe hypoglycemic episodes at 1 year.

146 Hypoglycemic episodes correlate with injury severity and

147 od glucose-confirmed (<56 mg/dL) symptomatic hypoglycemic episodes during the maintenance period.

148 odes were recorded, with moderate and severe hypoglycemic episodes grouped together.

149 Patients with one or more hypoglycemic episodes had longer hospitalization, as wel

150 and reduces weight without increasing major hypoglycemic episodes in patients with inadequately cont

151 Whether minor hypoglycemic episodes increase risk of dementia is unkno

152 Three severe hypoglycemic episodes occurred during the closed-loop ph

153 Fewer and less severe hypoglycemic episodes occurred in the traditional-thresh

154 llitus (T1DM) experience, on average, 2 to 3 hypoglycemic episodes per week.

155 ts with type 2 diabetes, a history of severe hypoglycemic episodes was associated with a greater risk

156 3.33]), and the proportions of patients with hypoglycemic episodes were 22.5% vs 31.6% (difference, -

157 2.85]), and the proportions of patients with hypoglycemic episodes were 9.7% vs 14.7% (difference, -5

158 e (< 4.0 mmol/L) and severe (</= 2.2 mmol/L) hypoglycemic episodes were recorded, with moderate and s

159 Group C (three patients with fasting hypoglycemic episodes) displayed very low rates of insul

160 ur patients with fasting and/or postprandial hypoglycemic episodes) showed qualitatively normal respo

161 Group B (three patients with fasting hypoglycemic episodes) was mainly characterized by large

162 ved mean glycemic levels, with less frequent hypoglycemic episodes, among both adults and adolescents

163 red glucose levels and frequent asymptomatic hypoglycemic episodes.

164 41), or 3 or more (3+; n = 17) prior severe hypoglycemic episodes.

165 isodes of diabetic ketoacidosis and frequent hypoglycemic episodes.

166 ine U100 in reducing the rate of symptomatic hypoglycemic episodes.

167 ions often result in adverse weight gain and hypoglycemic episodes.

168 ted in a reduced rate of overall symptomatic hypoglycemic episodes.

169 ld contribute to arrhythmias during clinical hypoglycemic episodes.

170 change in body weight, and rate of confirmed hypoglycemic episodes.

171 Atf4 null mice are hypoglycemic, even before substantial changes in fat con

172 stratified based on whether they developed a hypoglycemic event (random glucose level < 60 mg/dL) dur

173 terval) is significantly associated with the hypoglycemic event in each subject, overcoming the intel

174 ents (all in the control group) had a severe hypoglycemic event; no patients had diabetic ketoacidosi

175 Forty severe hypoglycemic events (<2.2 mmol/L [<40 mg/dL]) occurred d

176 aggressive control had a higher incidence of hypoglycemic events (4 vs 30; P < 0.0001).

177 The primary end points were the number of hypoglycemic events (defined as a sensor glucose value o

178 glycemic control increases the incidence of hypoglycemic events and does not result in any significa

179 ed more QALYs (16.68 vs. 16.58) due to fewer hypoglycemic events and fewer medications.

180 the primary endpoint of freedom from severe hypoglycemic events and HbA(1c) <= 6.5% or reduced by >=

181 ll transplant recipients were free of severe hypoglycemic events and maintained hemoglobin A1c (HbA1c

182 tegy is expected to present a lower risk for hypoglycemic events compared to KATP channel blockers.

183 onylurea to insulin was associated with more hypoglycemic events compared with insulin alone, but thi

184 The mean number of hypoglycemic events did not differ between the trial gro

185 Hypoglycemic events from 1980-2002 were collected and re

186 sity score-matched patients with one or more hypoglycemic events had greater inflammatory and metabol

187 Severe hypoglycemic events have been associated with increased

188 The baseline rate of severe and moderate hypoglycemic events in the pump-only group was 20.7 vs 1

189 Nocturnal hypoglycemic events occurred 31.8% less frequently in th

190 No serious hypoglycemic events occurred in either group; one episod

191 to 16 years) showed no progressively severe hypoglycemic events or diagnoses of insulinoma.

192 Hypoglycemic events that were recorded as adverse events

193 The mean AUC for nocturnal hypoglycemic events was 37.5% lower in the threshold-sus

194 ts were lower (P = 0.002) and rates of major hypoglycemic events were about 50% reduced (P < 0.001) i

195 e group vs 27 (18%) in the placebo group and hypoglycemic events were infrequent (2 [1%] vs 4 [3%], r

196 Patients with one or more hypoglycemic events were matched with patients not exper

197 type 2 (T2DM) is the increased occurrence of hypoglycemic events which, if left untreated, may cause

198 meal-stimulated C-peptide AUC, insulin use, hypoglycemic events, and immunologic responses.

199 C-peptide secretion, reduced insulin use and hypoglycemic events, and induced favorable immunologic p

200 n hemoglobin A(1c) levels (primary outcome), hypoglycemic events, depression, quality of life, fear o

201 the glycated hemoglobin level, the number of hypoglycemic events, the ratio of fasting proinsulin to

202 For serious hypoglycemic events, there was no significant associatio

203 exogenous insulin administration, and fewer hypoglycemic events.

204 e potential to reduce the incidence of major hypoglycemic events.

205 the area under the curve (AUC) for nocturnal hypoglycemic events.

206 level of serum glucose, and the incidence of hypoglycemic events.

207 ses, thereby increasing the risk for further hypoglycemic events.

208 lpha-cell UCP2 deletion perturbs the fasting/hypoglycemic glucagon response and shows that UCP2 is ne

209 VMH were assessed during a hyperinsulinemic-hypoglycemic glucose clamp study in chronically catheter

210 his purpose, hyperinsulinemic euglycemic and hypoglycemic glucose clamps were performed on separate d

211 were equally excited or inhibited by 5-HT at hypoglycemic glucose levels in vitro.

212 glycemic- (glucose approximately 5.5 mmol/l) hypoglycemic (glucose approximately 2.8 mmol/l) clamp st

213 ti-inflammatory, antioxidant, antimicrobial, hypoglycemic, healing-promoting, and immune-boosting pro

214 when arterial blood perfusing it is hypoxic, hypoglycemic, hypercapnic, or acidic.

215 f the young type II (MODY-II) and persistent hypoglycemic hyperinsulinemia of infancy (PHHI).

216 d Oxford method before the initiation of the hypoglycemic-hyperinsulinemic clamp protocol and during

217 ounterregulatory responses from a subsequent hypoglycemic (HYPO) clamp.RESULTSLow and intermediate MM

218 uding anti-cancer, anti-viral, anti-oxidant, hypoglycemic, hypo-lipidemic, and anti-inflammatory acti

219 cose level less than 3.9 mmol/L (<70 mg/dL) (hypoglycemic) in the previous 24 hours were identified u

220 All 1943 normoglycemic and transiently hypoglycemic infants (23-42 weeks' gestation) were eligi

221 lter, deep vein thrombosis prophylaxis, oral hypoglycemic intensification, cholesterol medication int

222 ood glucose was reduced from 5 (90 mg/dl) to hypoglycemic levels of 2.8 mmol/L (50 mg/dl) for 1 hour

223 , HbA1c was normalized, and time spent while hypoglycemic (<70 mg/dL) was nearly abolished as indicat

224 Although 83% of first hypoglycemic meals were preceded by 5 min dips in VMH (b

225 bin concentration of at least 6.5% or use of hypoglycemic medication (with or without insulin).

226 Information about hypoglycemic medication before or during pregnancy was n

227 nd followed longitudinally for initiation of hypoglycemic medication over 1 year after beginning cort

228 ng normal fasting glucose (<100 mg/dl and no hypoglycemic medication use) or abnormal fasting glucose

229 bnormal fasting glucose (>/=100 mg/dl and/or hypoglycemic medication use).

230 NODAT was defined as the use of hypoglycemic medication, a random plasma glucose level m

231 abetes was defined as patients not requiring hypoglycemic medication, fasting glucose below 7 mmol/L,

232 on and treatment algorithms with concomitant hypoglycemic medications.

233 t initially were neither diabetic nor taking hypoglycemic medications.

234 common antihypertensive, lipid-lowering, and hypoglycemic medications.

235 grafts were less sensitive to gemcitabine in hypoglycemic mice compared with hyperglycemic mice.

236 creatinine, hyperglycemia managed with oral hypoglycemics, minor wound infection, and hyperuricemia

237 ecretion were not affected by glucose level, hypoglycemic MPCCs upregulated CYP3A4 enzyme activity as

238 insulinemic-hypoglycemic clamps in which the hypoglycemic nadir, 2.48 +/- 0.06 mmol/l, was reached at

239 HbA1c, mean glucose and median percent time hypoglycemic on CGM were unchanged with CSII, SD glucose

240 ty among other and in vivo antihypertensive, hypoglycemic or anti-inflammatory activity.

241 d autonomic failure in response to recurrent hypoglycemic or glucopenic events.

242 horter for long-term diabetics who used oral hypoglycemics or insulin.

243 re, and mortality than burn patients without hypoglycemic (p < 0.05).

244 9.1% (223/225) concordance in characterizing hypoglycemic patients.

245 Clear evidence of hypoglycemic physiological counterregulation was first d

246 xty-three percent of LQT2 patients developed hypoglycemic plasma glucose levels (<70 mg/dL) versus 36

247 The GIR required to maintain the hypoglycemic plateau was higher in nNOS knockout than wi

248 The hypoglycemic potential of blueberry and pomegranate juic

249 The hypoglycemic proportion in the vGMS period was 36% lower

250 ons larger than 50mg/dl and about 12% in the hypoglycemic range (<50mg/dl).

251 duced blood glucose levels into the markedly hypoglycemic range in overnight-fasted, streptozotocin-t

252 M, average percent time in hyperglycemic and hypoglycemic range was larger in RYGBP (respectively, 4.

253 responding glucose concentrations lie in the hypoglycemic range.

254 t associated with an IG concentration in the hypoglycemic range.

255 9+/-6) per brain section were present in P14 hypoglycemic rats (p<0.01, each).

256 During hypoglycemia, recurrently hypoglycemic rats exhibited a 49-63% reduction in glucag

257 that high-intensity exercise in recurrently hypoglycemic rats increases levels of a number of protei

258 recent hypothesis based on in vivo data from hypoglycemic rats is that it is the decrease in zinc cos

259 (GAD), in the VMH of control and recurrently hypoglycemic rats.

260 vented the sucrose-induced late postprandial hypoglycemic response and the compensatory free fatty ac

261 ecreased, glucose tolerance improved and the hypoglycemic response to insulin was enhanced in CeA LV-

262 Both insulin signaling and the hypoglycemic response to insulin were similar between HK

263 ken to assess the impact of interrupting the hypoglycemic response to PH on liver regeneration in mic

264 oral insulin delivery, leading to a notable hypoglycemic response.

265 to counterregulatory failure in recurrently hypoglycemic (RH) and diabetic rats.

266 Hypoglycemic risk was similar to that of other agents.

267 w approaches for designing GKAs with reduced hypoglycemic risk.

268 utcome was the combined incidence of severe (hypoglycemic seizure or coma) and moderate hypoglycemia

269 Affected children present in infancy with hypoglycemic seizures after brief periods of fasting or

270 Here we studied mechanisms of control of hypoglycemic seizures induced by insulin injection in fa

271 in the function of the SNR, leading thus to hypoglycemic seizures.

272 s uses a specialized venom insulin to induce hypoglycemic shock in its prey.

273 ith otherwise sublethal doses of LPS induced hypoglycemic shock in mice within 1-2 h.

274 njected into fish, the venom insulin elicits hypoglycemic shock, a condition characterized by dangero

275 re school of fish simultaneously experiences hypoglycemic shock, this should directly facilitate capt

276 his hypothesis, we treated SKO mice with the hypoglycemic sodium-glucose cotransporter 2 (SGLT2) inhi

277 the patients spent 77 +/- 18 min per 24 h in hypoglycemic states (<3.9 mmol/L glucose) with 36 +/- 10

278 s patients experience both hyperglycemic and hypoglycemic states.

279 creatic beta cells to prevent both hyper-and hypoglycemic states.

280 Percentage of patients taking oral hypoglycemics, statins, and angiotensin-converting enzym

281 ter repolarization abnormalities for a given hypoglycemic stimulus despite comparable sympathoadrenal

282 counterregulation in response to a standard hypoglycemic stimulus.

283 ounterregulatory responses to a standardized hypoglycemic stimulus.

284 nephrine response when given 24 h before the hypoglycemic study.

285 rowth hormone, and noradrenaline, as well as hypoglycemic symptoms and cognitive function, were simil

286 ay contribute to increased susceptibility to hypoglycemic symptoms in RYGB surgery subjects.

287 upon oral glucose stimulation and increased hypoglycemic symptoms.

288 production (EGP, using 6,6-D2-glucose), and hypoglycemic symptoms.

289 h oral corticosteroids, 25 (1.21%) initiated hypoglycemic therapy compared with 5 of 2666 patients (0

290 erglycemia that is detected and treated with hypoglycemic therapy in the tertiary ocular inflammation

291 Other risk factors for the initiation of hypoglycemic therapy included older age (RR [per each ad

292 glucose concentrations below a user-defined hypoglycemic threshold.

293 Gender-matched patients with oral hypoglycemic-treated (T2OH) and insulin-treated type 2 d

294 ) for at least 5 years and be receiving oral hypoglycemic treatment or insulin.

295 Ten patients with type 1 diabetes with hypoglycemic unawareness received intraportal allogeneic

296 an emerging therapy for type 1 diabetes and hypoglycemic unawareness.

297 Postdonation, DM requiring oral hypoglycemics was diagnosed in 7 (15%) donors and insuli

298 Because RLIP76(-/-) mice are hypoglycemic, we studied the role of RLIP76 in insulin r

299 the human condition, the SUR-1(-/-) mouse is hypoglycemic when fasted and hyperglycemic when glucose-

300 ease in growth hormone and become profoundly hypoglycemic when fasted for 18-23 h.